Therapeutic targeting of the complement system in age‐related macular degeneration: a review
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
The last decade has produced pivotal change in our understanding of the molecular mechanisms underlying age‐related macular degeneration (AMD), a leading cause of global blindness. In this time, the complement system has featured as a unifying theme for several elements of new evidence: initially, the discovery of complement proteins within drusen and subsequently, the association between AMD and mutations in various complement pathway genes, most notably complement factor H. Increasingly, a wealth of data are pointing towards a role for chronic local inflammation and complement activation in the patho‐aetiology of AMD. These findings have paved the way for the exploration of a new paradigm of therapy in AMD management; targeting of specific molecular constituents in the complement pathway thus producing dampening or inhibition of the inflammatory response. Such an approach has the potential to intervene earlier in the disease process and ideally before vision is compromised. In this review we discuss the role of the complement system in AMD, novel therapies in preclinical evaluation and clinical trial, and whether these have a part to play in reducing the burden of disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522 · cited 1×
“Although these are effective modalities, a significant drawback in their utility is the need for repeated intraocular injection (and exposure to associated risks) to maintain therapeutic benefit.(25,26) Vascular endothelial growth factor trap is a new form of VEGF inhibitor currently in phase III clinical trial, and m…”
BackgroundComplement factor H polymorphism and age-related macular degeneration
Edwards, A. O., Ritter, R., Abel, K. J., Manning, A., Panhuysen, C., & Farrer, L. A. (2005) · Science · doi:10.1126/science.1110189 · Cited by 2,449
Complement factor H variant increases the risk of age-related macular degeneration
Haines, J. L., Hauser, M. A., Schmidt, S., Scott, W. K., Olson, L. M., Gallins, P., Spencer, K. L., Kwan, S. Y., Noureddine, M., Gilbert, J. R., et al. (2005) · Science · doi:10.1126/science.1110359 · Cited by 2,424
Hageman, G. S., Anderson, D. H., Johnson, L. V., Hancox, L. S., Taiber, A. J., Hardisty, L. I., Hageman, J. L., Stockman, H. A., Borchardt, J. D., Gehrs, K. M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501536102 · Cited by 1,961
Hageman, G. (2001) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(01)00010-6 · Cited by 1,265 · cited 1×
“This led to the development of an ‘inflammation’ model for AMD in which drusen were considered the by-products of complement-driven inflammatory processes at the level of the RPE-Bruch’s membrane interface.(13) Validation of this hypothesis occurred in early 2005 when a simultaneous convergence of independent research…”
ResultThe AMD Genetics Clinical Study Group, Gold, B., Merriam, J. E., Zernant, J., Hancox, L. S., Taiber, A. J., Gehrs, K., Cramer, K., Neel, J., Bergeron, J., et al. (2006) · Nature Genetics · doi:10.1038/ng1750 · Cited by 1,075 · cited 1×
“The population-attributable risk for AMD in individuals with the CFH polymorphism is approximately 50%, and combined analysis of the CFH and CFB/C2 haplotypes is predictive of disease in 74% of all AMD cases.(15) In addition to the highrisk CFB/C2 haplotype, Gold et al.”
BackgroundComplement C3 variant and the risk of age-related macular degeneration
Yates, J. R. W., Sepp, T., Matharu, B. K., Khan, J. C., Thurlby, D. A., Shahid, H., Clayton, D. G., Hayward, C., Morgan, J., Wright, A. F., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072618 · Cited by 829 · cited 2×
“Histological and biochemical studies of drusen discovered that various components of the complement system were identifiable as molecular constituents of the characteristic extracellular deposits found in early AMD.10,11 In addition, eyes obtained from human donors diagnosed with a complement-related renal disorder, m…”
BackgroundAnderson, D. H., Radeke, M. J., Gallo, N. B., Chapin, E. A., Johnson, P. T., Curletti, C. R., Hancox, L. S., Hu, J., Ebright, J. N., Malek, G., et al. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2009.11.003 · Cited by 727
The Role of Complement in the Development of Systemic Lupus Erythematosus
Manderson, A. P., Botto, M., & Walport, M. J. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104549 · Cited by 538 · cited 1×
“Additionally, there is increasing evidence that complement is involved in many immune-based diseases, systemic lupus erythematosus being a wellstudied example.(8) Complement deficiency has also been implicated in the plaque formation associated with Alzheimer’s disease and other neurodegenerative conditions.”
BackgroundBora, P. S., Sohn, J.-H., Cruz, J. M. C., Jha, P., Nishihori, H., Wang, Y., Kaliappan, S., Kaplan, H. J., & Bora, N. S. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.1.491 · Cited by 249
Cited by
The NHGRI GWAS Catalog, a curated resource of SNP-trait associations
Welter, D., MacArthur, J., Morales, J., Burdett, T., Hall, P., Junkins, H., Klemm, A., Flicek, P., Manolio, T., Hindorff, L., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1229 · Cited by 2,707
“This association between the degenerative disease and inflammation pathways has since been verified in other studies and is now showing promising results as a therapeutic target (2).”
ResultValidating therapeutic targets through human genetics
Plenge, R. M., Scolnick, E. M., & Altshuler, D. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4051 · Cited by 712
Complement, a target for therapy in inflammatory and degenerative diseases
Morgan, B. P., & Harris, C. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4657 · Cited by 431
STEC-HUS, atypical HUS and TTP are all diseases of complement activation
Noris, M., Mescia, F., & Remuzzi, G. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.195 · Cited by 383
Bringing genome-wide association findings into clinical use
Manolio, T. A. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3523 · Cited by 351
Metadata
- Authors
- Troutbeck, R., Al‐Qureshi, S., & Guymer, R. H.
- Venue
- Clinical & Experimental Ophthalmology
- Publisher
- Wiley
- Published
- 2012-01
- Volume
- 40
- Issue
- 1
- Pages
- 18-26
- ISSN
- 1442-6404 (ISSN-L)
- 1442-9071
- OpenAlex
- W1576158588
- Cited by
- 57
- References
- 13
- FWCI
- 9.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic targeting of the complement system in age‐related macular degeneration: a review. https://app.cochat.ai/papers/10.1111/j.1442-9071.2011.02581.x
- The paper
- Troutbeck, R., Al‐Qureshi, S., & Guymer, R. H. (2012). Therapeutic targeting of the complement system in age‐related macular degeneration: a review. Clinical & Experimental Ophthalmology. https://doi.org/10.1111/j.1442-9071.2011.02581.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.